

Bypassing inhibitors with FVIIa

Intrinsic pathway

Surface
HK
PK

FVIIa




FIG. 1

FVII Modifications




FIG. 2

FVII Modifications

SKI-1 site:	P6 R/K	P5 X	P4 R/K	P3 X	P2 L/V/F	P1 Z	P1' ↓	P2'
w.t. FVII	Ser	Lys	Pro	Gln	Gly	Arg	Ile	Val
Mutations:	R/K	Lys	R/K	Gln	L/V/F	Arg	Ile	Val

FIG. 3

Clotting time (sec)

293




Fig. 4A

Hep3B





Fig. 4B

293 cell supernates



1:100 diluted thromboplastin times

Fig. 5

Clotting time (sec)




Fig. 6A




Fig. 6B

Modified aPTT assay

Beige/SCID mice




Fig. 7

FVIII k/o mice




Fig. 8

PTT assay




FIG. 9